Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.

The Prostate - 1 Feb 2007

Jorgenson Eric, Deitcher Steven R, Cicek Mine, Liu Xin, Plummer Sarah, Casey Graham, Witte John S

Abstract excerpt

BACKGROUND: Variation in the expression of plasminogen activator inhibitor type-1 (PAI-1) is associated with many human diseases, including several types of cancer. In particular, tumor cell overexpression of PAI-1 has been found to inhibit prostate cancer tumor growth, angiogenesis, and metastasis in mouse models. Normal host cell expression of PAI-1 is influenced by the 4G/5G insertion/deletion polymorphism in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Family Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Michigan

Share to Plasminogen Activator Inhibitor 1

Share to Prostatic Neoplasms

Share to Siblings

Share to Surveys and Questionnaires

Source

Identifiers

PMID: 17044080
DOI: 10.1002/pros.20512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.PMID 17044080Read ↗

PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.Semantic proximity Read ↗

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.Semantic proximity Read ↗

Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.Semantic proximity Read ↗

4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.Semantic proximity Read ↗

Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference.Semantic proximity Read ↗

PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.Semantic proximity Read ↗

The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1.Semantic proximity Read ↗

Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.Semantic proximity Read ↗

The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery DiseaseSemantic proximity Read ↗

What is the impact of plasminogen activator inhibitor type 1 (PAI-1) gene polymorphism on gynecological malignancies: a retrospective studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.